Study finds ‘substantial revenues’ for cancer drugs in granted pediatric exclusivity
Regulatory NewsJeff Craven
Government/legislationPediatric productsPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)Regulatory NewsJeff CravenGovernment/legislationPediatric productsPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)